Open AccessThe role of ADAMTS ‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study
Author(s) -
Obermeier Hanna L.,
Riedl Julia,
Ay Cihan,
Koder Silvia,
Quehenberger Peter,
Bartsch Rupert,
Kaider Alexandra,
Zielinski Christoph C.,
Pabinger Ingrid
Publication year - 2019
Publication title -
research and practice in thrombosis and haemostasis
Language(s) - English
Resource type - Journals
ISSN - 2475-0379
DOI - 10.1002/rth2.12197
Subject(s) - medicine , adamts , von willebrand factor , hazard ratio , cancer , gastroenterology , univariate analysis , percentile , thrombosis , proportional hazards model , confidence interval , oncology , platelet , thrombospondin , metalloproteinase , multivariate analysis , matrix metalloproteinase , statistics , mathematics
Essentials Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a higher risk of venous thrombosis. Low levels of ADAMTS‐13 and/or increased VWF in cancer patients are associated with worse survival.Background Cancer‐associated venous thromboembolism ( VTE ) is an important complication in the course of a malignant disease. Low ADAMTS ‐13 (a disintegrin‐like and metalloproteinase with thrombospondin type 1 motif 13) and increased von Willebrand Factor ( VWF ) levels in cancer patients have been described numerously. Objectives Investigation of the influence of ADAMTS ‐13 and VWF on the probability of VTE and survival in malignancy. Patients/Methods In the framework of the ongoing prospective Cancer and Thrombosis Study ( CATS ) ADAMTS ‐13 activity and VWF antigen levels were investigated in cancer patients. Results In total, 795 patients with various tumor types (364 female/431 male, median age 62 years) were included; of those, 56 developed VTE and 359 patients died during a median follow‐up time of 730 days. The hazard ratio ( HR ) of VTE per doubling of VWF level was 1.56 (95% confidence interval [ CI ] 1.13‐2.16) in multivariable competing risk analysis. ADAMTS ‐13 levels showed no correlation with the incidence of VTE in univariate competing risk analysis. The HR of mortality per doubling of VWF level was 1.46 (95% CI 1.28‐1.66) and per SD increment of ADAMTS‐13was 0.90 (95% CI 0.81‐1.00) in multivariable Cox regression analysis. Patients with VWF >75th percentile and concomitant low (<25th percentile) or medium (25‐75th percentile) ADAMTS ‐13 values had the highest probability of mortality ( HR 4.31 and 4.75, respectively). Conclusions High VWF levels were significantly associated with the risk of developing VTE in cancer patients, whereas ADAMTS ‐13 was not. Low ADAMTS ‐13 and increased VWF levels were independently associated with worse overall survival.